V iruses are the leading cause of central nervous system (CNS) infections, ahead of bacteria, parasites, and fungal agents (1, 2). They are responsible for a wide spectrum of neurological disorders, ranging from the frequent and benign aseptic meningitis due to enteroviruses (EV) to the rare but serious herpes simplex virus (HSV)-caused encephalitis (3-5). PCR has been recognized as the reference method for the diagnosis of viral CNS infections (6-10). Gene amplification by PCR allows both sensitive and specific virus detection in the cerebrospinal fluid (CSF). It also offers the rapid virological diagnosis required to improve therapeutic management by antiviral therapy in order to limit brain necrosis in cases of herpes simplex virus encephalitis or to increase cost savings in hospitalized cases of enterovirus-related aseptic meningitis during the epidemic season (7, 8, 11, 12) . Moreover, it has been shown that quantitation of viral nucleic acid by real-time PCR assay of CSF is useful in monitoring the effectiveness of antiviral therapy, as well as for establishing the prognosis of the disease (13-15). However, the small volume of CSF available, combined with the wide number of DNA or RNA viruses potentially responsible for meningitis or encephalitis, makes it challenging to complete an exhaustive diagnostic profile. Currently, the virological diagnosis is determined through combinations of multiple PCR and reverse transcription-PCR assays, which lead to a virological detection in only 45% to 52% of clinically suspected CNS infections (16, 17) . A comprehensive virologic diagnostic testing method is needed for rapid and broad viral detection and quantitation in CSF samples of patients hospitalized for CNS infections.
V
iruses are the leading cause of central nervous system (CNS) infections, ahead of bacteria, parasites, and fungal agents (1, 2) . They are responsible for a wide spectrum of neurological disorders, ranging from the frequent and benign aseptic meningitis due to enteroviruses (EV) to the rare but serious herpes simplex virus (HSV)-caused encephalitis (3) (4) (5) . PCR has been recognized as the reference method for the diagnosis of viral CNS infections (6) (7) (8) (9) (10) . Gene amplification by PCR allows both sensitive and specific virus detection in the cerebrospinal fluid (CSF). It also offers the rapid virological diagnosis required to improve therapeutic management by antiviral therapy in order to limit brain necrosis in cases of herpes simplex virus encephalitis or to increase cost savings in hospitalized cases of enterovirus-related aseptic meningitis during the epidemic season (7, 8, 11, 12) . Moreover, it has been shown that quantitation of viral nucleic acid by real-time PCR assay of CSF is useful in monitoring the effectiveness of antiviral therapy, as well as for establishing the prognosis of the disease (13) (14) (15) . However, the small volume of CSF available, combined with the wide number of DNA or RNA viruses potentially responsible for meningitis or encephalitis, makes it challenging to complete an exhaustive diagnostic profile. Currently, the virological diagnosis is determined through combinations of multiple PCR and reverse transcription-PCR assays, which lead to a virological detection in only 45% to 52% of clinically suspected CNS infections (16, 17) . A comprehensive virologic diagnostic testing method is needed for rapid and broad viral detection and quantitation in CSF samples of patients hospitalized for CNS infections.
This study retrospectively assessed the clinical performance of a new technology coupling PCR amplification with electrospray ionization-time of flight mass spectrometry analysis (PCR-MS) for the diagnosis of viral CNS infections (18, 19) . Three hundred twenty-seven CSF specimens taken from patients hospitalized in two French university hospital centers for clinically suspected CNS infections were retrospectively analyzed using the PCR-MS technique. The results obtained by PCR-MS analysis were compared to those of the qualitative routine PCR assays used prospectively and to those of real-time quantitative PCR assays performed retrospectively.
MATERIALS AND METHODS
Study design. Cerebrospinal fluid samples collected by the virology laboratories of the university hospitals of Toulouse and Reims were retrospectively selected because (i) they had been categorized as positive or negative by routine PCR assays for detection of the main neurotropic viruses and (ii) a minimum volume of 300 l remained for each of them. The selected samples were nucleic acid extracted, followed by PCR-MS analysis at the virology laboratory of the Saint-Louis hospital (Paris). The nucleic acid extracts corresponding to positive or discordant results obtained for routine PCR techniques and PCR-MS for CSF sample analyses were sent back to the virology laboratory of Reims in order to be tested using a third molecular assay that allows a viral load assessment. Clinical specimens. , and HHV-6), enterovirus, and JC virus (JCV) by in-house and commercially available PCR assays used in daily practice in the two laboratories (Table 1) (20) (21) (22) (23) (24) (25) (26) . CSF samples had been routinely divided in aliquots and stored at Ϫ80°C since the date of collection.
Among these 327 CSF samples, 229 had prospectively tested positive for single (n ϭ 225) and multiple (n ϭ 4) viral infections with the routinely used PCR assays, whereas 98 were negative. The distribution of the virus-positive CSF samples selected for the present investigation is shown in Table 2 .
PCR-MS. CSF samples were retrospectively analyzed with the PLEX-ID system (Abbott Molecular, Abbott Park, IL), as previously reported (18, 19) . Briefly, RNA and DNA were extracted from 300 l of the clinical specimens using the PLEX-ID total nucleic acid isolation kits on the PLEX-ID FH and SP instruments and recovered in 200 l. For each clinical sample, 80 l of nucleic acids was then distributed by the PLEX-ID fluid handler into 8 reaction wells of 96-well assay plates and amplified with the Viral IC Spectrum II assay (developed by Abbott Molecular, IL, but not yet commercially available), containing primers targeted to adenovirus, HHV-1 to -8, polyomaviruses BK and JC, parvovirus B19 (PVB19), and EV (Table 3) . Cycling was done on the PLEX-ID TC (Mas- tercycler ProS; Eppendorf) according to the manufacturer's instructions. After desalting and purification, amplicons were analyzed by using the PLEX-ID analyzer. Methanol-based aerosols containing denatured ionized amplicons were sprayed into the mass spectrometer. The molecular weight of the amplicons was determined by an electrospray ionization-time of flight mass spectrometer and converted to base composition by database analysis. The virus was then identified by bioinformatics analysis of the base composition signatures produced by the virus target genes in each sample (27, 28) . Viral load assessment was obtained by quantifying the total number of amplicons against an internal calibrant with a known copy number that is included in every well. The internal calibrant competes with the amplicon for the same primers and PCR reagents; it additionally serves as an internal PCR control to confirm negative results (19) .
Discrepancy methods used for analysis of discordant results between routine PCR assays and PCR-MS. CSF samples were tested with a third molecular technique if they displayed either (i) discordant results between prospective and retrospective analyses or (ii) additional viruses detected with PCR-MS that were not included in the prospectively used PCR panel. The same nucleic acid extracts as used for PCR-MS analysis were tested either with endpoint PCR (JC/BK consensus kit; Argene bioMérieux, Verniolle, France) or real-time quantitative PCR (RT-qPCR) assays for HSV-1 and -2, VZV, CMV, EBV, HHV-6, HHV-7, PVB19, adenovirus, and EV, allowing viral load assessment in virus-positive CSF samples, except for HHV-7 (HSV1 HSV2 VZV R-Gene, CMV HHV6,7,8 R-Gene, EBV R-Gene, and Adenovirus R-Gene; Argene bioMérieux, Verniolle, France) (Table 1) (29, 30) .
The same real-time quantitative PCR techniques were also used to determine the viral load levels in positive samples by both routine PCR assays and PCR-MS in order to compare them with those assessed in the samples displaying discordant results.
Statistical analyses. The accuracy of the PCR-MS in detecting neurotropic viruses in CSF samples was determined by sensitivity and specificity, considering the routine PCR assays used for prospective analysis of CSF samples as the reference method. The kappa test was also used for measuring the agreement between the PCR-MS system and routine PCR assay. The Spearman's rank correlation was used to evaluate linear associations between viral loads assessed with the PCR-MS and the RT-qPCR assays used as the third analytical technique. Statistical analyses were carried out with SAS software, version 8.2 (SAS Institute, Cary, NC). Results were considered significant for two-sided P values of Ͻ0.05.
RESULTS

Analysis of the 327 selected CSF samples by the PCR-MS system.
Among the 229 CSF samples that prospectively tested positive using routine PCR assays, the PCR-MS system identified 218 viruses in 190 specimens ( Table 2 ). The PCR-MS assay showed results concordant with those of routine PCR techniques for 187 viruses (81.7%), corresponding to 183 positive CSF samples (79.9%). The kappa coefficients between the PCR-MS system and routine PCR assays appeared to be higher than 0.80 for HSV, VZV, and EV and 0.34 for EBV (Table 4) . In comparison to the routine PCR assays, the PCR-MS demonstrated sensitivity of above 90% for HSV and VZV, 80% for EV, and about 30% for EBV. The specificity ranged from 97% for HSV and EBV to 99% for VZV and EV. The low number of samples positive for CMV, HHV6, and JCV did not allow us to assess the accuracy of the PCR-MS in detecting these neurotropic viruses in CSF samples (Table 4) . Moreover, PCR-MS identified 26 coinfections, whereas only 4 had been detected by routine PCR techniques (P Ͻ 0.01). These coinfections consisted of 24 double infections and 2 triple infections. Among the 98 negative CSF samples identified by routine PCR assays, 10 classical neurotropic viruses were detected with PCR-MS (10/98 [10.2%]). Interestingly, PCR-MS identified 4 HSV CNS infections that were undetected by routine PCR assays (Table 2) .
Finally, among the 327 CSF samples tested, PCR-MS identified 16 instances of viruses that were not initially included in the panel of neurotropic viruses detected by routine PCR assays (Table 2) . These newly detected viruses were HHV-7 (n ϭ 13), PVB19 (n ϭ 2), and adenovirus (n ϭ 1) ( Table 2) . 
Analysis of discrepant results between routine PCR techniques and PCR-MS using a third molecular technique.
Clinical samples demonstrating results that were discrepant between routine PCR techniques and PCR-MS were analyzed with a third molecular technique consisting of either endpoint (JCV) or RTqPCR assays that allow virus detection and quantitation, except for HHV-7. Overall, 73 results were discordant between routine PCR techniques and PCR-MS (Table 4) .
Forty-six viral infections prospectively diagnosed by routine PCR techniques were not detected retrospectively by PCR-MS. Among these 46 routine PCR-positive and PCR-MS-negative CSF samples, 17 (37%) were confirmed positive by a third PCR assay, whereas 29 (63%) remained undetectable ( Table 4) . Nine of the 18 EBV-and 8 of the 25 EV-positive CSF samples that were not detected retrospectively with PCR-MS were confirmed by RT-qPCR (Table 4 Conversely, 27 neurotropic viruses were detected by PCR-MS alone. Nine of these 27 viral detections (33.3%) were confirmed by the third molecular technique used to analyze discrepant samples ( Table 4) .
Comparison of viral load assessment between PCR-MS and real-time quantitative PCR assays. Correlation analysis of the viral load levels obtained by PCR-MS and RT-qPCR assays was performed for CSF samples positive for HSV, VZV, EBV, and EV.
The quantitative values obtained with RT-qPCR and PCR-MS were compared and showed poor correlation with r 2 , ranging from 0.003 (P ϭ 0.77) for HSV to 0.415 for EBV (P ϭ 0.08) (data not shown).
DISCUSSION
The aim of this work was to assess the performance characteristics of a new test coupling multiplex PCR amplification with electrospray ionization-time of flight mass spectrometry analysis (PCR-MS) for the diagnosis of viral CNS infections in comparison with routine PCR assays used as reference methods. Among the 229 virus-positive CSF samples, the PCR-MS results were well correlated with the results of routine PCR techniques for HSV, VZV, and EV detection, demonstrating kappa coefficients greater than or equal to 0.8. The agreement was, however, weaker for EBV detection (kappa coefficient ϭ 0.34), since only 8 of the 26 EBVpositive CSF specimens selected were retrospectively detected by PCR-MS. This suggests a sensitivity defect of the viral IC spectrum II kit regarding this virus (Table 4) .
Among the 229 positive CSF samples tested, the PCR-MS system failed to detect 46 viruses identified by routine PCR techniques (Table 4) . Three hypotheses can be proposed to explain these discrepancies, as follows. (i) Nucleic acid degradation occurred either during the storage of the samples from the date of collection or at the time of sample thawing-this hypothesis could be particularly true for samples with low viral loads (101 [44%] of the 229 positive CSF samples selected for this study displayed a viral load of Ͻ500 copies/ml by RT-qPCR) and RNA viruses, such as EV, which were not detected retrospectively in 25 of the 154 positive samples. (ii) The PCR-MS technology has a lower sensitivity than routine PCR assays-the quantitation of EBV and EV viral load levels revealed that they were significantly higher in the concordant CSF samples that were positive by both techniques than in discordant CSF samples not detected retrospectively by the PCR-MS. (iii) There was a higher concentration of nucleic acids in extracts used for prospective analysis by routine classical techniques than in those used for retrospective PCR-MS analysis-the ratio between the CSF volume subjected to extraction and the elution volume of nucleic acids ranged from 2 (Toulouse) to 4 (Reims) for routine PCR analyses, whereas it was only 1.5 for PCR-MS analysis, leading to signal loss, particularly for CSF samples with low viral loads.
Two main strengths of the PCR-MS technology have been highlighted in the present investigation on CSF samples. First, this new technology significantly improved the detection of multiple viral infections in comparison to the results of routine PCR assays (26 versus 4, P Ͻ 0.01). These coinfections mainly involved EV (33, 34) . The literature on PVB19 (n ϭ 2) is much more extensive. Many neurological manifestations have been described in patients infected with PVB19, including encephalitis, aseptic meningitis, vasculitis, and peripheral neuropathy, involving mostly children and, in one-third of the cases, immunocompromised patients (35) . Adenoviruses (n ϭ 1) are opportunistic viruses responsible for severe disseminated infections in immunocompromised patients, particularly in bone marrow transplant recipients (36) . Their involvement in immunocompetent patients is limited to rare cases of aseptic meningitis (37) . Overall, the use of this innovative technology combining PCR and mass spectrometry could drastically increase the panel of pathogens detected in comparison with those detected by routine PCR assays. In a recent study, this new technology allowed the detection and semiquantitation in cardiac tissues of 84 different common or uncommon viruses, including confirmed neurological pathogens, such as dengue virus, West Nile virus, and Japanese or St. Louis encephalitis viruses (19) . The addition of emerging viruses in neurological infectious disease, such as Nipah virus, Hendrah virus, or parechoviruses, to the viral IC spectrum II kit panel, as well as the combined detection of bacteria, fungi, and parasites, would make this new technology more attractive and could facilitate its implementation in clinical microbiology laboratories (38, 39) . The quantitative aspect of the PCR-MS technology is, however, more questionable. The quantitative values of RT-qPCR and PCR-MS were compared and showed poor correlation, with r 2 less than or equal to 0.415 for all targets. The ability of the PCR-MS technology to generate quantitative data in the CSF did not seem to be reliable through the results obtained in the present work.
The qualitative approach proposed by the PCR-MS therefore implicates this new technology as a rapid-screening, broad-spectrum method. In fact, the results concerning all 13 viral species detected by the viral IC spectrum II assay can be given to the clinician within 6 to 8 h after the arrival of the sample in the laboratory. A single technician can carry out this new technology using only one CSF aliquot of 300 l. In this way, PCR-MS technology could find its place in clinical virology laboratories as a first-line test to perform a rapid and broad virological diagnosis in intensive care unit patients with severe disease or in immunocompromised patients at risk for developing a severe infection potentially induced by a wide range of viral species (40) . Moreover, PCR-MS technology could be the second-line test used for neurological infections in immunocompetent patients when conventional molecular techniques detecting the most common pathogens, such as HSV, VZV, EBV, and EV, are negative. Following the qualitative analysis by PCR-MS, allowing a rapid implementation of appropriate medical care, an RT-qPCR would be performed in order to assess the viral load in the CSF for prognosis and quantitative monitoring of the disease under proper potential antiviral therapy (13) (14) (15) . However, the sensitivity defect of the PCR-MS regarding EBV and EV detection identified in our study could be a limitation of its use in its present form as a first-line test in clinical practice, since sensitivity at least equivalent to that of the current molecular methods is mandatory. Moreover, the cost of the PLEX-ID platform could also limit its implementation in many clinical microbiology laboratories, either as a widely used first-line technique or as a second-line test whose cost would then add to the molecular techniques used routinely.
In conclusion, our results demonstrated that PCR-MS analysis is a valuable tool to identify the main common neurotropic viruses responsible for meningitis and encephalitis in hospitalized pediatric and adult patients. However, we observed lower sensitivity for the detection of EBV and EV by the PCR-MS method. The results of this study suggest that multiplex molecular platforms, such as PCR-MS, may allow for a greater understanding of the pathophysiology of CNS viral infections by allowing for a better assessment of the clinical implications of viral coinfections of the CNS and an increased understanding of the potential pathogenicity of neglected neurotropic viruses.
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